Taxane-induced pulmonary toxicity
- Talmadge E King, Jr, MD
Talmadge E King, Jr, MD
- Editor-in-Chief — Pulmonary and Critical Care Medicine
- Section Editor — Interstitial Lung Disease
- Dean, School of Medicine
- Vice Chancellor, Medical Affairs
- University of California San Francisco
- Section Editors
- Kevin R Flaherty, MD, MS
Kevin R Flaherty, MD, MS
- Section Editor — Interstitial Lung Disease
- Associate Professor of Medicine
- University of Michigan Health System
- Reed E Drews, MD
Reed E Drews, MD
- Section Editor — Complications of Cancer
- Associate Professor of Medicine
- Harvard Medical School
- Deputy Editors
- Diane MF Savarese, MD
Diane MF Savarese, MD
- Senior Deputy Editor — UpToDate
- Deputy Editor — Oncology and Palliative Care
- Clinical Instructor of Medicine
- Harvard Medical School
- Helen Hollingsworth, MD
Helen Hollingsworth, MD
- Deputy Editor — Pulmonary, Critical Care, and Sleep Medicine
- Associate Professor of Medicine
- Boston University School of Medicine
The taxanes, paclitaxel (Taxol), nanoparticle albumin-bound paclitaxel (nabpaclitaxel [Abraxane]), docetaxel (Taxotere), and cabazitaxel (Jevtana), are anti-microtubulin drugs that have a broad range of antitumor activity. These agents have the potential to induce pulmonary injury through a variety of mechanisms:
●The most common pulmonary toxicity, interstitial pneumonitis, can develop within days to weeks of receiving paclitaxel or docetaxel, or it may arise later in the course of therapy . In contrast, interstitial pneumonitis seems to be less common with nabpaclitaxel and with cabazitaxel, a semisynthetic taxane derivative used for treatment of advanced prostate cancer.
●A syndrome of capillary leakage, resulting in peripheral edema, noncardiogenic pulmonary edema, and pleural effusions, has also been reported with docetaxel but not with the other taxanes.
●Reactions that occur during or shortly after infusion of an antineoplastic agent can be categorized as hypersensitivity/allergic reactions (associated with mast cell/basophil activation) and standard infusion reactions (cytokine mediated) (table 1). The clinical signs and symptoms often include the lungs, and they overlap, although the mechanisms are different. Patients with symptoms and signs to suggest mast cell/basophil mediation (eg, urticaria, angioedema, wheezing, stridor) are at risk for life-threatening anaphylaxis should rechallenge be undertaken (table 2). The evaluation of reactions during or shortly after infusion of taxanes is presented in detail elsewhere. (See "Infusion reactions to systemic chemotherapy".)
Taxane-induced interstitial pneumonitis and capillary leakage syndrome will be reviewed here. An overview of chemotherapy-induced infusion reactions (which may present with respiratory symptoms) and general issues related to interstitial pneumonitis in adults are presented separately. (See "Infusion reactions to systemic chemotherapy" and "Approach to the adult with interstitial lung disease: Clinical evaluation" and "Approach to the adult with interstitial lung disease: Diagnostic testing" and "Acute interstitial pneumonia (Hamman-Rich syndrome)" and "Idiopathic interstitial pneumonias: Clinical manifestations and pathology".)
Subscribers log in hereLiterature review current through: Nov 2017. | This topic last updated: Jan 09, 2017.References
- Bielopolski D, Evron E, Moreh-Rahav O, et al. Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature. J Chemother 2017; 29:113.
- Wang GS, Yang KY, Perng RP. Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Br J Cancer 2001; 85:1247.
- Fujimori K, Yokoyama A, Kurita Y, et al. Paclitaxel-induced cell-mediated hypersensitivity pneumonitis. Diagnosis using leukocyte migration test, bronchoalveolar lavage and transbronchial lung biopsy. Oncology 1998; 55:340.
- Ostoros G, Pretz A, Fillinger J, et al. Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature. Int J Gynecol Cancer 2006; 16 Suppl 1:391.
- Ramanathan RK, Belani CP. Transient pulmonary infiltrates: a hypersensitivity reaction to paclitaxel. Ann Intern Med 1996; 124:278.
- Khan A, McNally D, Tutschka PJ, Bilgrami S. Paclitaxel-induced acute bilateral pneumonitis. Ann Pharmacother 1997; 31:1471.
- Yasuda K, Igishi T, Kawasaki Y, et al. Phase II trial of weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Oncology 2003; 65:224.
- Ayoub JP, North L, Greer J, et al. Pulmonary changes in patients with lymphoma who receive paclitaxel. J Clin Oncol 1997; 15:2476.
- Thomas AL, Cox G, Sharma RA, et al. Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. Eur J Cancer 2000; 36:2329.
- Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer 2002; 94:847.
- Ochoa R, Bejarano PA, Glück S, Montero AJ. Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review. J Med Case Rep 2012; 6:413.
- Tamiya A, Naito T, Miura S, et al. Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. Anticancer Res 2012; 32:1103.
- Peddi PF, Cho M, Wang J, et al. Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma. J Gastrointest Oncol 2013; 4:370.
- Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 2006; 17:372.
- Harries M, Moss C, Perren T, et al. A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer. Br J Cancer 2004; 91:627.
- Graziano SL, Herndon JE 2nd, Socinski MA, et al. Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901. J Thorac Oncol 2008; 3:158.
- Yasuda K, Igishi T, Kawasaki Y, et al. Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments. Oncology 2004; 66:347.
- Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008; 26:4244.
- Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26:1642.
- Chen YM, Shih JF, Perng RP, et al. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 2006; 129:1031.
- Harvey V, Mouridsen H, Semiglazov V, et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 2006; 24:4963.
- Storaas E, Holmaas G, Gravdal K, et al. Lethal pneumonitis after docetaxel chemotherapy: case report and review of the literature. Acta Oncol 2013; 52:1034.
- Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 2004; 22:2061.
- Bolis G, Scarfone G, Polverino G, et al. Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial. J Clin Oncol 2004; 22:686.
- Stemmer SM, Cagnoni PJ, Shpall EJ, et al. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial. J Clin Oncol 1996; 14:1463.
- McNeish IA, Kanfer EJ, Haynes R, et al. Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours. Br J Cancer 2004; 90:1169.
- Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012; 30:2055.
- Kanaji N, Tadokoro A, Kita N, et al. Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival. J Cancer Res Clin Oncol 2016; 142:1855.
- Watanabe N, Niho S, Kirita K, et al. Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia. Cancer Chemother Pharmacol 2015; 76:69.
- Azuma Y, Tamiya M, Shiroyama T, et al. Nanoparticle Albumin-bound Paclitaxel+Carboplatin Therapy for Small Cell Lung Cancer Combined with Squamous Cell Carcinoma and Interstitial Lung Disease. Intern Med 2015; 54:2911.
- Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 2008; 109:329.
- Katakami N, Takiguchi Y, Yoshimori K, et al. Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group. J Thorac Oncol 2006; 1:447.
- Dunsford ML, Mead GM, Bateman AC, et al. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 1999; 10:943.
- Li J, Juliar B, Yiannoutsos C, et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol 2005; 23:1185.
- Takeda K, Negoro S, Tamura T, et al. Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol 2009; 20:835.
- Briasoulis E, Froudarakis M, Milionis HJ, et al. Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support. Respiration 2000; 67:680.
- Yu TK, Whitman GJ, Thames HD, et al. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients. J Natl Cancer Inst 2004; 96:1676.
- Kalmadi S, McNeill G, Davis M, et al. Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. Med Oncol 2006; 23:507.
- Binder D, Hübner RH, Temmesfeld-Wollbrück B, Schlattmann P. Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials. Cancer Chemother Pharmacol 2011; 68:1575.
- Akerley W, Safran H, Zaner K, et al. Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer. Cancer 2006; 107:1050.
- Nakamura M, Koizumi T, Hayasaka M, et al. Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer. Cancer Chemother Pharmacol 2009; 63:1091.
- Onishi H, Kuriyama K, Yamaguchi M, et al. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung Cancer 2003; 40:79.
- Hanna YM, Baglan KL, Stromberg JS, et al. Acute and subacute toxicity associated with concurrent adjuvant radiation therapy and paclitaxel in primary breast cancer therapy. Breast J 2002; 8:149.
- Hasegawa T, Futamura Y, Horiba A, et al. A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer. J Radiat Res 2016; 57:50.
- Sekine I, Nokihara H, Sumi M, et al. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol 2006; 1:810.
- Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008; 26:5755.
- Taghian AG, Assaad SI, Niemierko A, et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst 2001; 93:1806.
- Beal K, Hudis C, Norton L, et al. Radiation pneumonitis in breast cancer patients treated with taxanes: does sequential radiation therapy lower the risk? Breast J 2005; 11:317.
- Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003; 21:2004.
- Wang S, Liao Z, Wei X, et al. Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. J Thorac Oncol 2008; 3:277.
- Kishida Y, Tsushima T, Endo M, et al. Risk Analysis of Pneumonitis in Taxane Therapy After Chemoradiotherapy for Patients With Metastatic or Recurrent Esophageal Cancer. Am J Clin Oncol 2015.
- Camus P. The Drug-Induced Respiratory Disease Website. www.pneumotox.com (Accessed on September 25, 2016).
- Camus P. Interstitial lung disease from drugs, biologics, and radiation. In: Interstitial Lung Disease, 5th, Schwarz MI, King TE, Jr. (Eds), People's Medical Publishing House - USA, Shelton, CT 2011. p.637.
- Fujimaki T, Kato K, Fukuda S, et al. Acute interstitial pneumonitis after implantation of paclitaxel-eluting stents: a report of two fatal cases. Int J Cardiol 2011; 148:e21.
- Ramanathan RK, Reddy VV, Holbert JM, Belani CP. Pulmonary infiltrates following administration of paclitaxel. Chest 1996; 110:289.
- Cleverley JR, Screaton NJ, Hiorns MP, et al. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol 2002; 57:292.
- Wong P, Leung AN, Berry GJ, et al. Paclitaxel-induced hypersensitivity pneumonitis: radiographic and CT findings. AJR Am J Roentgenol 2001; 176:718.
- Genestreti G, Di Battista M, Trisolini R, et al. A commentary on interstitial pneumonitis induced by docetaxel: clinical cases and systematic review of the literature. Tumori 2015; 101:e92.
- Camus P, White DA. Drugs and the lungs. In: Clinical Respiratory Medicine, 3rd, Albert RK, Spiro SG, Jett JR (Eds), Mosby Elsevier, Philadelphia 2008.
- Hasskarl J, Schroettner P, von den Berg A, et al. Severe Organizing Pneumonia after Two Cycles of Docetaxel as Fourth-Line Chemotherapy for Advanced Non-Small Cell Carcinoma of the Lung. Case Rep Oncol 2009; 2:12.
- Cobo Dols M, Gil Calle S, Alés Díaz I, et al. Bronchiolitis obliterans organizing pneumonia simulating progression in bronchioloalveolar carcinoma. Clin Transl Oncol 2006; 8:133.
- Nagata S, Ueda N, Yoshida Y, et al. Severe interstitial pneumonitis associated with the administration of taxanes. J Infect Chemother 2010; 16:340.
- Suzaki N, Hiraki A, Takigawa N, et al. Severe interstitial pneumonia induced by paclitaxel in a patient with adenocarcinoma of the lung. Acta Med Okayama 2006; 60:295.
- Leimgruber K, Negro R, Baier S, et al. Fatal interstitial pneumonitis associated with docetaxel administration in a patient with hormone-refractory prostate cancer. Tumori 2006; 92:542.
- Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995; 13:2643.
- Kenmotsu H, Tanigawara Y. Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose. Cancer Sci 2015; 106:497.
- Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16:187.
- Amathieu R, Tual L, Fessenmeyer C, Dhonneur G. [Docetaxel-induced acute pulmonary capillary-leak syndrome mimicking cardiogenic oedema]. Ann Fr Anesth Reanim 2007; 26:180.
- Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352:2302.
- Docetaxel injection. United States Prescribing Information. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on September 27, 2016).
- Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 1998; 16:3426.
- Kang RY, Yoo KS, Han HJ, et al. Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel. Support Care Cancer 2017; 25:429.
- Hosonaga M, Ito Y, Tokudome N, et al. A lower dose of docetaxel at 60 mg/m(2) could be continued longer for controlling peripheral edema in patients with metastatic breast cancer. Breast Cancer 2012; 19:329.
- Schweitzer VG, Juillard GJ, Bajada CL, Parker RG. Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer 1995; 76:1069.
- Malik SM, Collins B, Pishvaian M, et al. A phase I trial of bexarotene in combination with docetaxel in patients with advanced solid tumors. Clin Lung Cancer 2011; 12:231.
- INTERSTITIAL PNEUMONITIS
- Paclitaxel, docetaxel, and nabpaclitaxel
- - Incidence and impact of dose and schedule
- - Concomitant drugs
- - Concomitant radiotherapy
- - Patterns of disease
- - Clinical manifestations
- - Diagnostic evaluation
- - Treatment
- CAPILLARY LEAKAGE AND DOCETAXEL
- RADIATION RECALL
- SUMMARY AND RECOMMENDATIONS
- Interstitial pneumonitis
- Docetaxel-related capillary leakage